Pharmacological treatment of idiopathic pulmonary fibrosis–preclinical and clinical studies of pirfenidone, nintedanib, and N-acetylcysteine

M Myllärniemi, R Kaarteenaho - European clinical respiratory …, 2015 - Taylor & Francis
Three recent clinical trials on the pharmacologic treatment of idiopathic pulmonary fibrosis (IPF)
mark a new chapter in the management of patients suffering from this very severe fibrotic …

[HTML][HTML] The current position of surgical lung biopsy in the diagnosis of idiopathic pulmonary fibrosis

R Kaarteenaho - Respiratory research, 2013 - Springer
A new international statement defines usual interstitial pneumonia (UIP) which is a histological
and radiological form of idiopathic pulmonary fibrosis (IPF) more precisely than previously…

[HTML][HTML] Idiopathic pulmonary fibrosis-a systematic review on methodology for the collection of epidemiological data

…, ER Salomaa, U Hodgson, R Kaarteenaho… - BMC pulmonary …, 2013 - Springer
Background Recent studies suggest that the incidence of idiopathic pulmonary fibrosis (IPF)
is rising. Accurate epidemiological data on IPF, however, are sparse and the results of …

[HTML][HTML] Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis

…, S Korpela, U Zagai, MC Sköld, R Kaarteenaho - Respiratory …, 2016 - Springer
Background Idiopathic pulmonary fibrosis (IPF) is an incurable lung disease with a poor
prognosis. Fibroblasts and myofibroblasts are the key cells in the fibrotic process. Recently two …

Cadherin-11–mediated adhesion of macrophages to myofibroblasts establishes a profibrotic niche of active TGF-β

…, P Pakshir, B Wu, S Boo, M Kiebalo, R Kaarteenaho… - Science …, 2019 - science.org
Macrophages contribute to the activation of fibroblastic cells into myofibroblasts, which
secrete collagen and contract the collagen matrix to acutely repair injured tissue. Persistent …

Demographics and survival of patients with idiopathic pulmonary fibrosis in the FinnishIPF registry

…, ER Salomaa, U Hodgson, R Kaarteenaho… - ERJ open …, 2019 - Eur Respiratory Soc
Idiopathic pulmonary fibrosis (IPF) is characterised by unpredictable disease course and poor
survival. After the introduction of novel antifibrotic drugs, the prognosis of patients with IPF …

Linoleic acid-derived lipid mediators increase in a female-dominated subphenotype of COPD

…, H Merikallio, R Kaarteenaho… - European …, 2016 - Eur Respiratory Soc
… (r=0.87; p=0.0009) and mRNA levels of enzymes putatively involved in their biosynthesis
(r=0.96; p=0.003). Leukotoxin levels correlated with goblet cell abundance (r=0.72; p=0.028). …

[HTML][HTML] Variable course of disease of rheumatoid arthritis-associated usual interstitial pneumonia compared to other subtypes

…, HP Kettunen, TA Selander, RL Kaarteenaho - BMC pulmonary …, 2016 - Springer
Background In rheumatoid arthritis-associated interstitial lung disease (RA-ILD), occurring
in 10 % of patients with patients with RA, usual interstitial pattern (UIP) has shown to …

[PDF][PDF] Leveraging global multi-ancestry meta-analysis in the study of idiopathic pulmonary fibrosis genetics

…, S Ripatti, M Pirinen, T Laitinen, R Kaarteenaho… - Cell genomics, 2022 - cell.com
The research of rare and devastating orphan diseases, such as idiopathic pulmonary
fibrosis (IPF) has been limited by the rarity of the disease itself. The prognosis is poor—the …

[HTML][HTML] Several high-resolution computed tomography findings associate with survival and clinical features in rheumatoid arthritis-associated interstitial lung disease

…, MS Kärkkäinen, TA Selander, RL Kaarteenaho - Respiratory …, 2018 - Elsevier
… (GGO) and the duration of RA (r = −0.308, p = 0.023). The extents of honeycombing (r =
0.266, p = 0.046), traction bronchiectasis (r = 0.333, p = 0.012) and architectural distortion (…